

UNUSUAL PHENOTYPE OF B CELLS IN THE
THYMUS OF NORMAL MICE

By MUNEO MIYAMA-INABA,*† SHO-ICHI KUMA,*§ KAYO INABA,||
HAJIME OGATA,* HIROSHI IWAI,* RYOJI YASUMIZU,*†
SHIGERU MURAMATSU,|| RALPH M. STEINMAN,†
AND SUSUMU IKEHARA*†

*From the *First Department of Pathology, †Department of Immunology, The Liver Research Center, §Department of Surgery, Kansai Medical University, Moriguchi, Japan; the ||Department of Zoology, Faculty of Science, Kyoto University, Kyoto, Japan; and the †Laboratory of Cellular Physiology and Immunology, Irvington House Institute, The Rockefeller University, New York, New York 10021*

The thymus is a central lymphoid organ for the differentiation of T cells. The thymus contains >95% thymocytes and trace numbers of other cells like macrophages, dendritic cells, and epithelial cells (1). Only a small number of Ig⁺ B cells are detected in normal thymi (1), but expanded numbers have been reported during disease. B cell follicles and numerous plasma cells have been reported in the thymus of patients with autoimmune diseases like myasthenia gravis and systemic lupus erythematosus (2-4), and similar findings have been noted in autoimmune-prone mice such as (NZB × NZW)F₁, MRL/Mp-*lpr/lpr* (MRL/*lpr*), and BXSB (5). In these pathologic situations, it has not been elucidated if the B cells infiltrate the thymus from the blood, or if the B cells originally are present in the thymus and expand as part of the disease.

We have begun a study of thymic B cells to determine their contribution to autoantibody formation. We have succeeded in enriching thymic B cells from normal mice and find that most of these lymphocytes have the unusual phenotype of the Ly-1 B cell subset, a subset previously implicated in autoantibody production (6, 7).

Materials and Methods

Mice. Female (BALB/c × DBA/2)F₁ (CD2F₁) and C57BL/6J (B6) mice were purchased from Japan Clea Corp. (Tokyo) and kept under specific pathogen-free conditions until use at 6-8 wk of age.

Antibodies. mAb to Thy-1.2 [F7D5] was purchased from Olac Ltd. (Bicester, United Kingdom). mAb to Thy-1.2 (30-H12, IgG2b), CD4 (GK 1.5, IgG2b), Lyt-2.2 or CD8 (HO-2.2, IgM), B220 or CD45R (RA3-3A1/6.1, IgM; 14-8, IgG2b), Ia (M5/114.15.2, IgG2b), and Mac-1 or CD11b (M1/70, IgG2b) were from the American Type Culture Collection (Rockville, MD). The mAbs were used for depletion or staining. FITC-coupled rabbit anti-mouse

This work was supported in part by a grant from the Japanese Ministry of Health and Welfare, a grant from the Naito Foundation, a grant from the Mitsubishi Foundation, and by a grant-in-aid from the Mochida Memorial Foundation for Medical and Pharmaceutical Research, a grant from Suzuken Memorial Foundation, the Science Research Promotion Fund of the Japan Private School Promotion Foundation (1987), by a grant-in-aid for cancer research 62015088 from the Ministry of Education, Science and Culture (1987), and by grants AG-03592, AG-05628, AG-05633, AI-19495, and AI-13013 from the National Institutes of Health.

μ -chain F(ab')₂ or FITC-rabbit anti-mouse Ig F(ab')₂ fragments were obtained from Cappel Laboratories (West Chester, PA), while biotinylated mouse anti-rat Ig κ mAb was from Zymed Laboratories (San Francisco, CA). Biotinylated anti-Lyt-1 or CD5 (53.7.3, IgG2a), biotin-anti-CD8 (53.6.7, IgG2a), FITC-avidin, and PE-avidin were from Becton Dickinson & Co. (Mountain View, CA). F(ab')₂ fragment of goat anti-mouse μ chain from Cappel Laboratories was used to stimulate B cells.

Cell Preparation. The connective tissue attached to thymic lobes was carefully peeled off to remove the parathymic lymph nodes. Thymocytes were prepared by gentle teasing onto a fine steel mesh, were washed twice in RPMI 1640 medium (Nissui, Tokyo, Japan), and suspended in medium with 10% FCS (HyClone Laboratories, Logan, UT). Cell suspensions were layered onto the 65% Percoll solution (Pharmacia Fine Chemicals, Uppsala, Sweden) (1) and centrifuged at 900 *g* for 20 min. The low-density cells (50–60% of the total) at the interface between the medium and the Percoll solution were collected, washed twice in RPMI 1640, and treated with a mixture of mAb to Thy-1.2, CD4, and CD8 (above) in the presence of rabbit complement. The mAb and dead cells were removed by washing twice in alkaline (pH 7.6–7.8) RPMI 1640. The resulting population was B cell enriched and T cell depleted (see Results). B cells from the spleen were prepared by the same T cell depletion procedure, with or without passage through Sephadex G10.

Proliferative Assays. Triplicate cultures of 10⁵ cells were incubated in 0.2 ml of RPMI 1640 medium containing 10% FCS, penicillin, streptomycin, and 50 μ M 2-ME in flat-bottomed Corning microculture plates. The stimuli were: 25 μ g/ml LPS (*Escherichia coli* 055:85 Difco Laboratories Inc., Detroit, MI), 2 μ g/ml Con A (Pharmacia Fine Chemicals), or anti- μ (10 μ g/ml) plus rIL-4 or purified BSF-1 (generously donated by Dr. T. Honjo, Kyoto University, and Dr. K. Kumagai, Tohoku University). Proliferation was measured on the third day by pulsing with 1 μ Ci of [³H]thymidine for 10 h.

Cytofluorography. Cells were suspended in PBS with 2% FCS and 0.05% azide and stained according to a triple-layer method using rat mAb, biotin-mouse anti-rat Ig κ , and FITC-avidin. The controls were stained with FITC- or PE-avidin without first mAb, or with nonreactive, isotype-matched mAb (see Results). To double label for Ly-1 and surface Ig, the cells were stained first with FITC-rabbit anti-mouse μ chain F(ab')₂ fragment followed by normal rat Ig to block the reactivity of anti- μ with the subsequent antibody and to reduce binding to Fc receptors. Then the cells were stained with biotin-anti-Ly-1 and PE-avidin. Nonreactive control biotin-mAb were to Thy-1 and CD8. The cells were analyzed on a FACStar (B-D Automated Immunochemistry, Salt Lake City, UT).

Results

Enrichment of B Cells from Normal Thymus. To enrich the trace population of thymic B cells, suspensions were separated on Percoll density gradients. Most sIg⁺ thymic B cells were recovered in the low-density fraction, whereas only a supopulation of splenic B cells floated under similar conditions. After treatment with a cocktail of anti-T cell mAb and complement, the frequency of sIg⁺ B cells rose from ~3% to >90% (below). The yield was ~1% of the starting thymus suspension.

B cell enrichment was evident by functional assays, i.e., proliferation to LPS and anti- μ plus IL-4. The starting thymocytes, the low-density fraction, and the B cell-enriched population were compared (Table I). The latter responded best to LPS, and to anti- μ plus IL-4, but was depleted of Con A reactivity. The low-density cells (50–60% of the total thymus cells) responded vigorously to Con A because most immunoincompetent thymocytes sedimented (not shown), but weakly to LPS and IL-4. The high-density population, even when treated with anti-T cell mAb and complement, failed to respond to the B cell stimuli (not shown).

Phenotype of Thymic B Cells. Cytofluorography was used to compare enriched preparations of thymic B cells with spleen B cells (Fig. 1). More than two of three of the

TABLE I
Enrichment of Thymic B Cells

Cells from thymus	Proliferative responses*						Ig-bearing cells [†]
	—	Anti- μ antibody (10 μ g/ml)	IL-4 (10 U/ml)	Anti- μ + IL-4	LPS (25 μ g/ml)	Con A (2 μ g/ml)	
Total cells	892	573	1,574	1,261	643	13,883	0.6
Low-density cells [§]	914	577	4,360	3,492	284	71,091	2.7
B cell-enriched cells	415	454	2,602	16,541	36,193	2,776	89.9

* Cells (10^5) were cultured with or without various kinds of stimulants for 72 h, and pulsed with [3 H]TdR for the last 10 h of the culture period. Numbers in the table represent mean cpm of triplicated cultures.

[†] Cells in each fraction were stained with FITC-conjugated rabbit anti-mouse Ig antibody.

[§] Low-density cells were obtained from the upper layer of the 65% Percoll gradient.

^{||} B cell-enriched cells were obtained from the low-density cells by treating them with anti-L3T4, anti-Lyt-2.2, and anti-Thy-1.2 mAbs plus complement.

thymic B cells coexpressed Lyt-1 (CD5), whereas most splenic B cells were Lyt-1⁻. The thymic B cells could also be killed with a cytotoxic anti-Lyt-1 mAb (not shown). Both thymic and splenic B cells had comparable levels of sIg (Fig. 2, *a* and *f*), but most of the thymic B cells had less B220 or CD45R (*b* vs. *g*) and Ia (*c* vs. *h*). Mac-1 [CD11b] and CD5 were found on most thymic B cells, which did not react with two isotype-matched control mAbs, GK1.5 anti-CD4 and 30-H12 anti-Thy-1 (*d* and *e*).

Discussion

We have been able to enrich the small number of thymic B cells (~1% of thymic suspensions) and have found that most have the features of Lyt-1 B cells. The latter




FIGURE 1. Two color FACS analysis of thymic and splenic B cells. Enriched populations of thymic and splenic B cells were treated successively with FITC-rabbit anti-mouse μ chain F(ab')₂ fragment, excess normal rat IgG, biotin-anti-Lyt-1 (CD5), and PE-avidin. The stained cells were fixed and analyzed on a FACStar cytofluorograph.




FIGURE 2. Phenotype of thymic and splenic B cells. Enriched populations of thymic (*top*) and splenic (*bottom*) B cells were stained with the different mAbs indicated on the panel and specified in Materials and Methods, followed by biotin-mouse anti-rat Ig κ and FITC-avidin. The designation [-] on the panels were controls that were unstained cells (*a* and *f*), FITC-avidin only (*b* and *g*), and biotin-mouse anti-rat Ig κ and FITC-avidin (*e* and *j*).

are a distinct population of CD11b⁺ and CD5⁺ lymphocytes which are detected in the peritoneal cavity but are hard to find in spleen, blood, and especially lymph nodes (6, 7). Similar results were obtained with thymi of C57BL/6 and young NZB mice, and from C57BL/6 mice varying in age from 3 to 8 wk (not shown). The staining of B cells for CD5 was specific, since no decrease was seen with an excess of rat Ig (500 μ g/ml) to block Fc receptors, and there was no staining with other anti-T cell mAbs like anti-Thy-1 CD8 and CD4. Furthermore, the majority of thymic B cells prepared by our procedure could be killed by anti-CD5 (but not anti-Thy-1.2, CD4, or CD8) mAb and complement. Other comparisons with conventional splenic B cells are that the thymic cells had less B220 and Ia antigens, a lower buoyant density in Percoll, and similar amounts of membrane μ . These results are consistent with those reported for Ly-1⁺ B cells in the peritoneal cavity (8, 9).

Our functional assays demonstrated that thymic B cells responded to B cell stimulants. However, the responses were much lower than spleen (not shown). In preliminary studies, Ly-1⁺ thymic B cells have been purified on the FACS and found to have little or no responsiveness either to LPS or to anti- μ and IL-4. Likewise, depletion with anti-Ly-1 and complement enhances the responsiveness of the thymic B cell preparation to these stimuli. Therefore Ly-1 B cells may not contribute to the functional assays that were used to help monitor our enrichment method (Table I).

Peripheral Ly-1⁺ B cells are known to be involved in "spontaneous" secretion of IgM, including autoreactive antibody (10). These B cells appear early in development (11) and are long lived (12). A regulatory role has been suggested in allotypic (13) and idiotypic cell-cell interactions (14-16). This being the case, it is possible that the Ig V region of thymic Ly-1 B cells shapes the repertoire of T cell antigen receptors by providing epitopes that correspond to antigen in association with self-

MHC. Alternatively, products of the Ly-1 B cell repertoire may function to eliminate or inactivate self-reactive T cells by providing internal images of self during T cell development. We are now studying the ontogeny of these thymic B cells to clarify their function in normal and autoimmune-prone mice.

Summary

A small number of B cells are found in the thymus of normal mice. A population of B lymphocytes could be enriched to >90% purity by isolating a low-density fraction on Percoll density gradients and then depleting T cells with a mixture of anti-Thy-1, CD4, and CD8 mAbs and complement. Enrichment was monitored by surface Ig staining and by functional studies (responsiveness to LPS, and to anti- μ plus IL-4). When the phenotype of these B cells was studied by flow cytometry, 60–80% had the phenotype Ly-1⁺ (CD5), Ia⁺, B220^{low} (CD45R), and Mac-1⁺ (CD 11b). In contrast, splenic B cells lacked CD5 and CD11b and expressed higher levels of B220 and Ia antigens. These results indicate that most thymic B cells have the phenotype of the Ly-1 B cell subset, which was identified previously as a trace subpopulation in some peripheral tissues and is thought to play a role in autoantibody formation.

The authors express their gratitude to Ms. K. Higuchi and Ms. K. Nomura for technical assistance, Ms. S. Ohya for manuscript preparation, and Mr. K. Kobayashi, Research Center of Kansai Medical University for the FACS studies.

Received for publication 11 April 1988.

References

1. Inaba, K., M. D. Witmer-Pack, M. Inaba, S. Muramatsu, and R. M. Steinman. 1988. The function of Ia⁺ dendritic cells, and Ia⁻ dendritic cell precursors, in thymocyte mitogenesis to lectin and lectin plus IL-1. *J. Exp. Med.* 167:149.
2. Fujii, N., Y. Itoyama, T. Tebira, and Y. Kuroiwa. 1983. Subsets of lymphoid cells in blood and thymus in myasthenia gravis. Monoclonal antibody analysis. *J. Neuroimmunol.* 4:151.
3. Vincent, A., H. C. Thomas, G. K. Scadding, and J. Newson-Davis. 1978. In vitro synthesis of anti-acetylcholine receptor antibody by thymic lymphocytes in myasthenia gravis. *Lancet.* i:305.
4. Williams, C. L., and V. A. Lennon. 1986. Thymic B lymphocyte clones from patients with myasthenia gravis secrete monoclonal striational autoantibodies reacting with myosin, alpha actinin, or actin. *J. Exp. Med.* 164:1043.
5. Ikehara, S., H. Tanaka, T. Nakamura, F. Furukawa, S. Inoue, K. Sekita, J. Shimizu, Y. Hamashima, and R. A. Good. 1985. The influence of thymic abnormalities on the development of autoimmune diseases. *Thymus.* 7:25.
6. Hayakawa, K., R. R. Hardy, D. R. Parks, and L. A. Herzenberg. 1983. The "Ly-1 B" cell subpopulation in normal, immunodeficient, and autoimmune mice. *J. Exp. Med.* 157:202.
7. Herzenberg, L. A., A. M. Stall, P. A. Lalor, C. Sidman, W. A. Moore, D. R. Parks, and L. A. Herzenberg. 1986. The Ly-1 B cell lineage. *Immunol. Rev.* 93:81.
8. Herzenberg, L. A., A. M. Stall, J. Braun, D. Weaver, D. Baltimore, L. A. Herzenberg, and R. Grosschedl. 1987. Depletion of the predominant B-cell population in immunoglobulin heavy-chain transgenic mice. *Nature (Lond.)* 329:71.
9. de la Hera, A., M. A. R. Marcos, M. L. Toribio, C. Marquez, M. L. Gaspar, and C.

- Martinez-A. 1987. Development of Ly-1⁺ B cells in immunodeficient CBA/N mice. *J. Exp. Med.* 166:804.
10. Hayakawa, K., R. R. Hardy, M. Honda, L. A. Herzenberg, A. D. Steinberg, and L. A. Herzenberg. 1984. Ly-1 B: functionally distinct lymphocytes that secrete IgM autoantibodies. *Proc. Natl. Acad. Sci. USA.* 81:2494.
 11. Hardy, R. R., and K. Hayakawa. 1986. Development of Ly-1 B and its human homolog, Leu-1 B. *Immunol. Rev.* 93:53.
 12. Braun, J. 1983. Spontaneous in vitro occurrence and long-term culture of murine B lymphoblastoid cell lines. *J. Immunol.* 130:2113.
 13. Okumura, K., K. Hayakawa, and T. Tada. 1982. Cell-to-cell interaction controlled by immunoglobulin genes. Role of Thy-1⁻, Lyt-1⁺, Ig⁺ (B) cell in allotype-restricted antibody production. *J. Exp. Med.* 156:443.
 14. Sherr, D. H., and M. A. Dorf. 1984. An idiotype-specific helper population that bears immunoglobulin, Ia, and Lyt-1 determinants. *J. Exp. Med.* 159:1189.
 15. Sherr, D. H., and S-T. Ju. 1986. Idiotype-specific helper cells (B_H) express immunoglobulin markers and employ T cell function-associated molecules. *J. Immunol.* 137:3406.
 16. Sherr, D. H., M. A. Dorf, M. Gibson, and C. L. Sidman. 1987. Ly-1 B helper cells in autoimmune "viable motheaten" mice. *J. Immunol.* 139:1811.